Shabir A Madhi1, Michelle J Groome2, Heather J Zar3, Constant N Kapongo4, Christine Mulligan3, Susan Nzenze2, David P Moore2, Elizabeth R Zell5, Cynthia G Whitney5, Jennifer R Verani5. 1. Medical Research Council: Respiratory & Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa National Institute for Communicable Diseases, Division of National Health Laboratory Service, Center for Vaccines and Immunology, Johannesburg, South Africa. 2. Medical Research Council: Respiratory & Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. 3. Department of Paediatrics and Child Health, Red Cross War Memorial Hospital, University of Cape Town, Cape Town, South Africa. 4. Ngwelezane Hospital, University of KwaZulu-Natal, KwaZulu Natal, South Africa. 5. Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Abstract
INTRODUCTION: We evaluated pneumococcal conjugate vaccine (PCV) effectiveness against hospitalisation for presumed bacterial pneumonia (PBP) in HIV-uninfected South African children. 7-valent PCV was introduced in April 2009 using a 2+1 schedule (doses at age 6, 14 and 39 weeks), superseded with 13-valent PCV in May 2011. METHODS: A matched case-control study was conducted at three public hospitals (Soweto, Cape Town and KwaZulu-Natal) between April 2009 and August 2012. PBP cases had either WHO defined radiographically confirmed pneumonia or 'other infiltrate' on chest radiograph with C-reactive protein ≥ 40 mg/L. Hospitalised controls were children admitted with a disease unlikely to be pneumococcal and matched for case age, site and HIV infection status. Age-matched community controls were enrolled from Soweto. Adjusted vaccine effectiveness (aVE) was estimated using conditional logistic regression. RESULTS: Of 1444 HIV-uninfected enrolled PBP cases, 1326 had ≥ 1 hospital controls (n=2075). Overall, aVE of an up-to-date PCV schedule was 20.1% (95% CI -9.3% to 41.6%) in children aged ≥ 8 weeks and 39.2% (95% CI 8.46% to 59.6%) among children 16-103 weeks of age. There were 889 PBP cases in Soweto with hospital controls and ≥ 1 community control (n=2628). The aVE using community controls was similar compared with hospital controls in Soweto, including 32.1% (95% CI 4.6% to 51.6%) and 38.4% (95% CI 7.7% to 58.8%), respectively, in age group ≥ 8 weeks and 52.7% (95% CI 25.7% to 69.9%) and 53.8% (95% CI 19.5% to 73.5%), respectively, in age group 16-103 weeks. CONCLUSIONS: PCV implemented using a 2+1 schedule in the routine infant immunisation programme was effective at preventing PBP in HIV-uninfected children. Effectiveness estimates were similar to efficacy measured by earlier randomised controlled trials using different vaccination schedules. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
INTRODUCTION: We evaluated pneumococcal conjugate vaccine (PCV) effectiveness against hospitalisation for presumed bacterial pneumonia (PBP) in HIV-uninfected South African children. 7-valent PCV was introduced in April 2009 using a 2+1 schedule (doses at age 6, 14 and 39 weeks), superseded with 13-valent PCV in May 2011. METHODS: A matched case-control study was conducted at three public hospitals (Soweto, Cape Town and KwaZulu-Natal) between April 2009 and August 2012. PBP cases had either WHO defined radiographically confirmed pneumonia or 'other infiltrate' on chest radiograph with C-reactive protein ≥ 40 mg/L. Hospitalised controls were children admitted with a disease unlikely to be pneumococcal and matched for case age, site and HIV infection status. Age-matched community controls were enrolled from Soweto. Adjusted vaccine effectiveness (aVE) was estimated using conditional logistic regression. RESULTS: Of 1444 HIV-uninfected enrolled PBP cases, 1326 had ≥ 1 hospital controls (n=2075). Overall, aVE of an up-to-date PCV schedule was 20.1% (95% CI -9.3% to 41.6%) in children aged ≥ 8 weeks and 39.2% (95% CI 8.46% to 59.6%) among children 16-103 weeks of age. There were 889 PBP cases in Soweto with hospital controls and ≥ 1 community control (n=2628). The aVE using community controls was similar compared with hospital controls in Soweto, including 32.1% (95% CI 4.6% to 51.6%) and 38.4% (95% CI 7.7% to 58.8%), respectively, in age group ≥ 8 weeks and 52.7% (95% CI 25.7% to 69.9%) and 53.8% (95% CI 19.5% to 73.5%), respectively, in age group 16-103 weeks. CONCLUSIONS: PCV implemented using a 2+1 schedule in the routine infant immunisation programme was effective at preventing PBP in HIV-uninfectedchildren. Effectiveness estimates were similar to efficacy measured by earlier randomised controlled trials using different vaccination schedules. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Eric D McCollum; Melissa M Higdon; Nicholas S S Fancourt; Jack Sternal; William Checkley; John De Campo; Anita Shet Journal: Pediatr Radiol Date: 2021-03-11
Authors: Abdullah H Baqui; Eric D McCollum; Samir K Saha; Arun K Roy; Nabidul H Chowdhury; Meagan Harrison; Abu Abdullah Mohammad Hanif; Nicole Simmons; Arif Mahmud; Nazma Begum; Salahuddin Ahmed; Ahad M Khan; Zabed Bin Ahmed; Maksuda Islam; Dipak Mitra; Abdul Quaiyum; Miguel A Chavez; Farhan Pervaiz; Catherine H Miele; Holly B Schuh; Rasheda Khanam; William Checkley; Lawrence H Moulton; Mathuram Santosham Journal: Gates Open Res Date: 2018-04-26
Authors: Eric D McCollum; Salahuddin Ahmed; Nabidul H Chowdhury; Syed J R Rizvi; Ahad M Khan; Arun D Roy; Abu Am Hanif; Farhan Pervaiz; Asm Nawshad U Ahmed; Ehteshamul H Farrukee; Mahmuda Monowara; Mohammad M Hossain; Fatema Doza; Bidoura Tanim; Farzana Alam; Nicole Simmons; Megan E Reller; Meagan Harrison; Holly B Schuh; Abdul Quaiyum; Samir K Saha; Nazma Begum; Mathuram Santosham; Lawrence H Moulton; William Checkley; Abdullah H Baqui Journal: BMJ Open Respir Res Date: 2019-04-15
Authors: Jennifer R Verani; Abdullah H Baqui; Claire V Broome; Thomas Cherian; Cheryl Cohen; Jennifer L Farrar; Daniel R Feikin; Michelle J Groome; Rana A Hajjeh; Hope L Johnson; Shabir A Madhi; Kim Mulholland; Katherine L O'Brien; Umesh D Parashar; Manish M Patel; Laura C Rodrigues; Mathuram Santosham; J Anthony Scott; Peter G Smith; Halvor Sommerfelt; Jacqueline E Tate; J Chris Victor; Cynthia G Whitney; Anita K Zaidi; Elizabeth R Zell Journal: Vaccine Date: 2017-04-22 Impact factor: 3.641
Authors: Jennifer R Verani; Abdullah H Baqui; Claire V Broome; Thomas Cherian; Cheryl Cohen; Jennifer L Farrar; Daniel R Feikin; Michelle J Groome; Rana A Hajjeh; Hope L Johnson; Shabir A Madhi; Kim Mulholland; Katherine L O'Brien; Umesh D Parashar; Manish M Patel; Laura C Rodrigues; Mathuram Santosham; J Anthony Scott; Peter G Smith; Halvor Sommerfelt; Jacqueline E Tate; J Chris Victor; Cynthia G Whitney; Anita K Zaidi; Elizabeth R Zell Journal: Vaccine Date: 2017-04-23 Impact factor: 3.641
Authors: Claire von Mollendorf; Stefano Tempia; Anne von Gottberg; Susan Meiring; Vanessa Quan; Charles Feldman; Jeane Cloete; Shabir A Madhi; Katherine L O'Brien; Keith P Klugman; Cynthia G Whitney; Cheryl Cohen Journal: PLoS One Date: 2017-07-03 Impact factor: 3.240
Authors: Melissa M Higdon; Laura L Hammitt; Maria Deloria Knoll; Henry C Baggett; W Abdullah Brooks; Stephen R C Howie; Karen L Kotloff; Orin S Levine; Shabir A Madhi; David R Murdoch; J Anthony G Scott; Donald M Thea; Amanda J Driscoll; Ruth A Karron; Daniel E Park; Christine Prosperi; Scott L Zeger; Katherine L O'Brien; Daniel R Feikin Journal: Clin Infect Dis Date: 2017-06-15 Impact factor: 9.079
Authors: Eric D McCollum; Salahuddin Ahmed; Arun D Roy; Nabidul H Chowdhury; Holly B Schuh; Syed J R Rizvi; Abu A M Hanif; Ahad M Khan; Arif Mahmud; Farhan Pervaiz; Meagan Harrison; Megan E Reller; Nicole Simmons; Abdul Quaiyum; Nazma Begum; Mathuram Santosham; William Checkley; Lawrence H Moulton; Abdullah H Baqui Journal: Vaccine Date: 2020-08-29 Impact factor: 3.641